Mark Rosenblum
SlowingNamed in filings at Company Ventures
- Board seats filed
- 5
all filings on record
Named in filings at Company Ventures
all filings on record
last 24 months
from a verified or cited source
| Terrarium | Digital health | January 2025 | None on file |
| NICO | Medical devices | September 2022 | None on file |
| Salarius Pharmaceuticals | Biotech & pharma | April 2022 | None on file |
| Urigen Pharmaceuticals | Biotech & pharma | July 2015 | KSN |
| Advaxis | Biotech & pharma | January 2012 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Mark Rosenblum on the board, based on 5 filed seats with a verified or cited source.